Movement Alert｜Twist Bioscience Corp Falls 5.1% in Regular Trading, Post-Earnings Bull-Bear Debate Extends High-Level Pullback

Market Focus08-07 03:30

On August 7, Twist Bioscience Corp fell 5.1% in regular trading, trading at $109.145/share, with turnover of $120 million. The decline extends the volatile post-earnings price action as the market continues to digest conflicting signals from the company's fiscal Q3 results.

The company reported Q3 revenue of $118.4 million, up 23.2% year-over-year and beating the analyst consensus of $114.5 million. However, EPS came in at a loss of $0.56, significantly worse than the expected loss of $0.50-$0.51 and a sharp reversal from the $0.33 per share profit in the year-ago period. The company raised its full-year revenue guidance to $456-$457 million and guided Q4 revenue to $123-$124 million, well above the FactSet consensus of $117.4 million.

Following the August 3 earnings release, shares initially plunged over 9% on the earnings miss before rebounding more than 6% on the strength of the revenue guidance. The current pullback reflects ongoing tension between strong top-line momentum and deteriorating profitability at elevated valuation levels. Evercore ISI had previously downgraded the stock to In Line from Outperform in July, raising its price target to $102.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1184421723?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 03:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184421723","market":"us","top_or_hot":-1,"title":"Movement Alert｜Twist Bioscience Corp Falls 5.1% in Regular Trading, Post-Earnings Bull-Bear Debate Extends High-Level Pullback","media":"Market Focus","content":"<p><p>On August 7, Twist Bioscience Corp fell 5.1% in regular trading, trading at $109.145/share, with turnover of $120 million. The decline extends the volatile post-earnings price action as the market continues to digest conflicting signals from the company's fiscal Q3 results.</p><p>The company reported Q3 revenue of $118.4 million, up 23.2% year-over-year and beating the analyst consensus of $114.5 million. However, EPS came in at a loss of $0.56, significantly worse than the expected loss of $0.50-$0.51 and a sharp reversal from the $0.33 per share profit in the year-ago period. The company raised its full-year revenue guidance to $456-$457 million and guided Q4 revenue to $123-$124 million, well above the FactSet consensus of $117.4 million.</p><p>Following the August 3 earnings release, shares initially plunged over 9% on the earnings miss before rebounding more than 6% on the strength of the revenue guidance. The current pullback reflects ongoing tension between strong top-line momentum and deteriorating profitability at elevated valuation levels. Evercore ISI had previously downgraded the stock to In Line from Outperform in July, raising its price target to $102.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Twist Bioscience Corp Falls 5.1% in Regular Trading, Post-Earnings Bull-Bear Debate Extends High-Level Pullback</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Twist Bioscience Corp Falls 5.1% in Regular Trading, Post-Earnings Bull-Bear Debate Extends High-Level Pullback\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-07 03:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 7, Twist Bioscience Corp fell 5.1% in regular trading, trading at $109.145/share, with turnover of $120 million. The decline extends the volatile post-earnings price action as the market continues to digest conflicting signals from the company's fiscal Q3 results.</p><p>The company reported Q3 revenue of $118.4 million, up 23.2% year-over-year and beating the analyst consensus of $114.5 million. However, EPS came in at a loss of $0.56, significantly worse than the expected loss of $0.50-$0.51 and a sharp reversal from the $0.33 per share profit in the year-ago period. The company raised its full-year revenue guidance to $456-$457 million and guided Q4 revenue to $123-$124 million, well above the FactSet consensus of $117.4 million.</p><p>Following the August 3 earnings release, shares initially plunged over 9% on the earnings miss before rebounding more than 6% on the strength of the revenue guidance. The current pullback reflects ongoing tension between strong top-line momentum and deteriorating profitability at elevated valuation levels. Evercore ISI had previously downgraded the stock to In Line from Outperform in July, raising its price target to $102.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TWST","symbol_name":"Twist Bioscience Corp","start_time":0,"source_url":"","article_id":"1184421723","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184421723","pubTimestamp":1786044616,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 7, Twist Bioscience Corp fell 5.1% in regular trading, trading at $109.145/share, with turnover of $120 million. The decline extends the volatile post-earnings price action as the market...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TWST":"Twist Bioscience Corp"},"translate_title":"走势警报|Twist Bioscience Corp 常规交易中下跌 5.1%，财报后牛熊辩论延长高位回调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TWST":1},"content_text":"On August 7, Twist Bioscience Corp fell 5.1% in regular trading, trading at $109.145/share, with turnover of $120 million. The decline extends the volatile post-earnings price action as the market continues to digest conflicting signals from the company's fiscal Q3 results.The company reported Q3 revenue of $118.4 million, up 23.2% year-over-year and beating the analyst consensus of $114.5 million. However, EPS came in at a loss of $0.56, significantly worse than the expected loss of $0.50-$0.51 and a sharp reversal from the $0.33 per share profit in the year-ago period. The company raised its full-year revenue guidance to $456-$457 million and guided Q4 revenue to $123-$124 million, well above the FactSet consensus of $117.4 million.Following the August 3 earnings release, shares initially plunged over 9% on the earnings miss before rebounding more than 6% on the strength of the revenue guidance. The current pullback reflects ongoing tension between strong top-line momentum and deteriorating profitability at elevated valuation levels. Evercore ISI had previously downgraded the stock to In Line from Outperform in July, raising its price target to $102.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1184421723","isCrawlerRequest":true}